AI is creating new opportunities across the pharmaceutical industry, but not every organisation is equally equipped to capitalise on them. The differentiator is not simply access to AI, but digital maturity; the strength of the infrastructure underpinning it. Those with mature, well-integrated systems and reliable data are better positioned to embed AI across the pharmaceutical value chain, accelerating everything from early-stage research and development to clinical trials.
For organisations with fragmented IT systems, inconsistent data and disconnected workflows, however, AI is unlikely to solve existing inefficiencies and could even expose existing weaknesses. The result is a widening divide between digitally mature organisations that can turn AI into a competitive advantage and those still building the foundations to do so.
AI is an amplifier, not a quick fix
The long-term competitive edge will be won by the pharma organisations that build AI into their digital transformation plans. Currently, nearly 60% of executives plan to increase generative AI investment [1], which is expected to create between $60 billion and $110 billion in annual economic value [2].
Yet, this rapid AI adoption is exposing just how unprepared many pharma organisations are to work in digitally connected setups. While some organisations are able to scale AI successfully, others find that weak data infrastructure limits their ability to make informed decisions and realise AI’s full potential.
AI as a test of digital maturity
The digital foundations for effective AI adoption are reliable data, connected systems, standardised processes, effective governance and clear accountability.
Where those foundations are in place, AI can significantly extend what existing digital platforms are capable of. Integrated and trustworthy data can be transformed into predictive insights, intelligent automation and faster, more informed decisions.
From operating silos to connected data governance
However, AI does not compensate for poor digital foundations. Inconsistent data, disconnected systems, unclear ownership and weak governance can limit AI’s effectiveness and introduce additional operational and regulatory risks.
This is creating a clear distinction between organisations that are building digital capability at an enterprise level and those pursuing one-off AI initiatives.
The differentiator is not who has the most AI pilots underway. It is who has created the infrastructure, governance and operating model needed to scale AI safely and effectively.
AI is becoming more than a technology opportunity. It is increasingly a litmus test of organisational digital maturity.
This divide is not necessarily determined by company size or budget. Many organisations already possess the technologies required to support AI adoption. The difference is often whether data, processes and governance have been connected across the enterprise. In many cases, digital maturity is less about deploying new technology and more about creating the conditions for existing technology to work together effectively.
From digital fatigue to proven value
The value of AI in pharma emerges most clearly when applied within connected, well-governed environments, enhancing everyday operations for better decision-making and risk management at scale.
Mikhail Nilov / Pexels
After years of transformation programmes, some pharmaceutical organisations are understandably sceptical of another wave of technology investment. However, AI can help renew the case for digital transformation, but only when it is applied to clearly defined operational problems and supported by connected, well-governed data.
In pharma, compliance is fundamental. AI can support a shift from reactive quality management towards more predictive approaches. However, use in a GxP environment depends on strong data integrity, traceability, validation and human oversight.
Emerging guidance, including the draft EU GMP Annex 22 [3], also makes it clear that different types of AI and different levels of risk require different controls.
In R&D, AI accelerates insight generation and informed prioritisation but is dependent on harmonised and traceable data across systems. In supply chains, it strengthens forecasting and reliability but relies on consistent master data and processes.
The true value AI can bring to pharmaceutical companies is when it is an extension of their digital backbone, not a shortcut around it. Ultimately, AI does not remove the need for strong operational discipline; it reinforces it.
But what is holding many pharma companies back from achieving digital maturity?
The complex regulatory landscape is an extra hurdle in the digitalisation race
Complex regulatory, organisational and skills challenges continue to slow digital progress. As one of the most highly regulated industries, pharmaceutical organisations must continually balance innovation, operational efficiency and compliance with evolving regulatory requirements. A challenge for many organisations is how best to ensure digital compliance with global regulatory frameworks such as EU GMP Annex 11 and FDA 21 CFR Part 11 without slowing implementation.
A growing shortage of data science skills
Limited expertise in data science, AI and cybersecurity is a constant barrier to digital transformation. However, the challenge extends beyond recruiting specialist AI talent. Many organisations also need business leaders, quality professionals and functional experts who understand how AI can be applied responsibly within regulated environments. Without this combination of technical capability, operational knowledge and governance expertise, organisations can struggle to move from experimentation to scaled adoption.
Finding candidates who combine deep pharmaceutical knowledge with AI skills remains difficult, and retaining experienced employees in a rapidly evolving digital environment adds to the challenge.
Addressing these challenges requires a coordinated strategy that blends technology investment with cultural transformation.
So, what are some ways pharma professionals can close the digital maturity gap?
1. Lead with organisational priorities before AI technology
Many organisations begin with technology and then search for a problem to solve. Digitally mature organisations take the opposite approach, identifying high-value operational challenges before determining where AI can create measurable impact.
In quality and regulatory functions, AI can help teams manage growing volumes of documentation and information more efficiently. However, success depends on clear ownership, reliable data and robust validation processes rather than the technology alone.
2. Data connectivity is key for strong operational architecture
AI is only as effective as the data and processes that underpin it. Before scaling AI initiatives, organisations should assess whether data is consistent, traceable and connected across functions.
AI-enabled demand sensing, risk prediction and scenario modelling can improve supply chain resilience, but these capabilities rely on trusted master data and standardised end-to-end processes across internal and partner networks.
3. Don’t treat governance as an afterthought
As AI adoption increases, governance cannot be treated as an afterthought. Organisations should define ownership, validation requirements, risk controls and decision-making responsibilities before solutions move into operation.
In GxP-regulated environments, AI can support more predictive approaches to quality and compliance, but only when supported by strong governance, data integrity and validation practices.
4. Scale up through connected capabilities
The goal should not be to launch more AI initiatives, but to build the organisational capability needed to scale them effectively. Successful organisations use early projects to develop repeatable ways of working, governance models and technical foundations.
Whether accelerating R&D through connected clinical data or enabling more personalised engagement across commercial and medical functions, long-term value comes from enterprise-wide capability rather than standalone AI experiments.
AI may be the catalyst, but digital maturity remains the differentiator
Pharmaceutical organisations that connect AI to trusted, governed data, controlled processes, accountable decision-making and measurable operational outcomes will be better positioned to scale it responsibly. When pharma organisations have the digital foundations in place to scale AI integrations, this is when AI investment can prove itself as a true operational and competitive advantage.
Author Bio
